All Luke Miels (GSK) articles
-
NewsGSK advances oncology efforts with $10.6bn Nuvalent acquisition
Multi-product oncology deal accelerates GSK’s entry into lung cancer.
-
NewsGSK to acquire BELLUS for £1.6 billion
A novel P2X3 antagonist is set to advance GSK's respiratory pipeline as part of its planned £1.6 billion acquisition of BELLUS Health.
-
NewsGSK to exclusively license novel oral antifungal
The only US Food and Drug Administration (FDA)-approved oral antifungal for vulvovaginal candidiasis will be exclusively licensed by GSK.